viewMaxCyte Inc

MaxCyte report 'extraordinary first half' with revenue 30% higher than same period last year

Maxcyte Inc's (LON:MXCT) Doug Doerfler talks to Proactive London about their full-year revenues which are on track to be 'slightly above' current market expectations.

Doerfler discusses what he describes as an 'extraordinary first half' with half year revenue 30% higher than the same period in 2019, which were 30% over 2018. There are now 11 commercial deals in total, which is a huge increase from four this time last year, with 90 clinical products under license, which is twice what MaxCyte had last year.

He goes on to explain the 'exciting increase' in their commercial activity, with revenue driven by high-margin recurring annual fees from its cell therapeutics business, instrument sales and clinical milestone payments.

Quick facts: MaxCyte Inc

Price: 950 GBX

Market: AIM
Market Cap: £900.5 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...


Market report: UK lockdown fears sink FTSE into a sea of red

The FTSE is in the red this Monday morning with fears prime minister, Boris Johnson, is reportedly considering a two-week mini-lockdown in England in a bid to stem the spread of the virus. We’ll find out later on this week. As a consequence - British Airways parent company, IAG, (LON:IAG) is...

on 21/9/20

2 min read